-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives initial payment of $125 million consisting of an upfront payment of$45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding$4 billion, as well as tiered royalties -Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and ...